Which hedge funds own BLTE? BELITE BIO INC, Q2 2026 13F holders
37 tracked hedge funds disclosed a position in BLTE (BELITE BIO INC) in their Q2 2026 13F filings, worth $1.2bn in total. The largest holder by portfolio weight is Darwin Global Management, Ltd. at 12.1% of its book. 14 opened a new position this quarter: Logos Global Management LP, Maverick Capital Ltd, Soleus Capital Management, L.P., Capricorn Fund Managers Ltd. 5 exited: Perceptive Advisors LLC, ADAR1 Capital Management, LLC, Aquatic Capital Management LLC.
- 37
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 14
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 5
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $135m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $32.2m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $1.2bn
- Combined value Sum of the holders' reported positions in the security.
- 3.0%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Perceptive Advisors LLC | 0.5% | $24.2m |
| ADAR1 Capital Management, LLC | 0.3% | $4.3m |
| Aquatic Capital Management LLC | 0.09% | $3.2m |
| Tudor Investment Corp ET AL | 0.0% | $254k |
| Farallon Capital Management, L.L.C. | 0.0% | $207k |
Ownership over time
Who discovered BLTE first? Beta
The run: Q2 2023 → Q3 2026, ×12
| RTW Investments, LP | Q4 2025 | – | +0.3 pts |
| Perceptive Advisors LLC | Q4 2025 | – | +0.1 pts |
| MPM Bioimpact LLC | Q4 2025 | – | 0.0 pts |
| Arrowpoint Investment Partners (Singapore) Pte. Ltd. | Q1 2026 | – | 0.0 pts |
| Verdad Advisers, LP | Q1 2026 | – | −0.1 pts |
| Balance Capital Partners L.P. | Q1 2026 | – | −0.1 pts |
| Paradigm Biocapital Advisors LP | Q1 2026 | – | −0.1 pts |
| Darwin Global Management, Ltd. high conviction | Q4 2025 | – | −0.4 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.